ATR Is a Therapeutic Target in Synovial Sarcoma
- 14 December 2017
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 77 (24) , 7014-7026
Abstract
Synovial sarcoma (SS) is an aggressive soft-tissue malignancy characterized by expression of SS18–SSX fusions, where treatment options are limited. To identify therapeutically actionable genetic dependencies in SS, we performed a series of parallel, high-throughput small interfering RNA (siRNA) screens and compared genetic dependencies in SS tumor cells with those in >130 non–SS tumor cell lines. This approach revealed a reliance of SS tumor cells upon the DNA damage response serine/threonine protein kinase ATR. Clinical ATR inhibitors (ATRi) elicited a synthetic lethal effect in SS tumor cells and impaired growth of SS patient-derived xenografts. Oncogenic SS18–SSX family fusion genes are known to alter the composition of the BAF chromatin–remodeling complex, causing ejection and degradation of wild-type SS18 and the tumor suppressor SMARCB1. Expression of oncogenic SS18–SSX fusion proteins caused profound ATRi sensitivity and a reduction in SS18 and SMARCB1 protein levels, but an SSX18–SSX1 Δ71–78 fusion containing a C-terminal deletion did not. ATRi sensitivity in SS was characterized by an increase in biomarkers of replication fork stress (increased γH2AX, decreased replication fork speed, and increased R-loops), an apoptotic response, and a dependence upon cyclin E expression. Combinations of cisplatin or PARP inhibitors enhanced the antitumor cell effect of ATRi, suggesting that either single-agent ATRi or combination therapy involving ATRi might be further assessed as candidate approaches for SS treatment. Cancer Res; 77(24); 7014–26. ©2017 AACR.Keywords
All Related Versions
This publication has 47 references indexed in Scilit:
- Targeting the ATR/CHK1 Axis with PARP Inhibition Results in Tumor Regression in BRCA-Mutant Ovarian Cancer ModelsClinical Cancer Research, 2017
- Molecular Pathways: Targeting ATR in Cancer TherapyClinical Cancer Research, 2015
- ARID1A Deficiency Impairs the DNA Damage Checkpoint and Sensitizes Cells to PARP InhibitorsCancer Discovery, 2015
- Chemical strategies for development of ATR inhibitorsExpert Reviews in Molecular Medicine, 2014
- Chromosome Instability Accounts for Reverse Metastatic Outcomes of Pediatric and Adult Synovial SarcomasJournal of Clinical Oncology, 2013
- Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trialThe Lancet, 2012
- Cell cycle regulation by the NEK family of protein kinasesJournal of Cell Science, 2012
- SWI/SNF nucleosome remodellers and cancerNature Reviews Cancer, 2011
- The function of BCL9 in Wnt/β-catenin signaling and colorectal cancer cellsBMC Cancer, 2008
- Identification of novel genes, SYT and SSX, involved in the t(X;18)(p11.2;q11.2) translocation found in human synovial sarcomaNature Genetics, 1994